Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma

We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m(2) PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxiciti...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidinger, M, Wenzel, C, Locker, G J, Muehlbacher, F, Steininger, R, Gnant, M, Crevenna, R, Budinsky, A C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364023/
https://www.ncbi.nlm.nih.gov/pubmed/11747325
http://dx.doi.org/10.1054/bjoc.2001.2149
_version_ 1782153850789036032
author Schmidinger, M
Wenzel, C
Locker, G J
Muehlbacher, F
Steininger, R
Gnant, M
Crevenna, R
Budinsky, A C
author_facet Schmidinger, M
Wenzel, C
Locker, G J
Muehlbacher, F
Steininger, R
Gnant, M
Crevenna, R
Budinsky, A C
author_sort Schmidinger, M
collection PubMed
description We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m(2) PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxicities were moderate. In view of these encouraging findings, further studies appear warranted. © 2001 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2364023
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23640232009-09-10 Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma Schmidinger, M Wenzel, C Locker, G J Muehlbacher, F Steininger, R Gnant, M Crevenna, R Budinsky, A C Br J Cancer Regular Article We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m(2) PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxicities were moderate. In view of these encouraging findings, further studies appear warranted. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-12 /pmc/articles/PMC2364023/ /pubmed/11747325 http://dx.doi.org/10.1054/bjoc.2001.2149 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Schmidinger, M
Wenzel, C
Locker, G J
Muehlbacher, F
Steininger, R
Gnant, M
Crevenna, R
Budinsky, A C
Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
title Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
title_full Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
title_fullStr Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
title_full_unstemmed Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
title_short Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
title_sort pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364023/
https://www.ncbi.nlm.nih.gov/pubmed/11747325
http://dx.doi.org/10.1054/bjoc.2001.2149
work_keys_str_mv AT schmidingerm pilotstudywithpegylatedliposomaldoxorubicinforadvancedorunresectablehepatocellularcarcinoma
AT wenzelc pilotstudywithpegylatedliposomaldoxorubicinforadvancedorunresectablehepatocellularcarcinoma
AT lockergj pilotstudywithpegylatedliposomaldoxorubicinforadvancedorunresectablehepatocellularcarcinoma
AT muehlbacherf pilotstudywithpegylatedliposomaldoxorubicinforadvancedorunresectablehepatocellularcarcinoma
AT steiningerr pilotstudywithpegylatedliposomaldoxorubicinforadvancedorunresectablehepatocellularcarcinoma
AT gnantm pilotstudywithpegylatedliposomaldoxorubicinforadvancedorunresectablehepatocellularcarcinoma
AT crevennar pilotstudywithpegylatedliposomaldoxorubicinforadvancedorunresectablehepatocellularcarcinoma
AT budinskyac pilotstudywithpegylatedliposomaldoxorubicinforadvancedorunresectablehepatocellularcarcinoma

Ejemplares similares